US6852508B1
(en)
|
1997-02-28 |
2005-02-08 |
Genetics Institute, Llc |
Chemokine with amino-terminal modifications
|
US6100387A
(en)
*
|
1997-02-28 |
2000-08-08 |
Genetics Institute, Inc. |
Chimeric polypeptides containing chemokine domains
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
CA2341029A1
(en)
*
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
AU773891C
(en)
|
1998-10-23 |
2005-02-17 |
Kirin-Amgen Inc. |
Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
|
US6660843B1
(en)
†
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
GB9824632D0
(en)
*
|
1998-11-10 |
1999-01-06 |
Celltech Therapeutics Ltd |
Biological compounds
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
ES2694002T3
(en)
*
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polypeptide comprising an Fc region of variant human IgG1
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
GB9908263D0
(en)
*
|
1999-04-13 |
1999-06-02 |
Binding Site The Limited |
Eliciting improved immune responses
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
WO2002043660A2
(en)
|
2000-11-28 |
2002-06-06 |
Mediummune, Inc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
CA2407083A1
(en)
|
2000-04-21 |
2001-11-01 |
Amgen Inc. |
Apo-ai/aii peptide derivatives
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
US6677136B2
(en)
*
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
CA2408617A1
(en)
|
2000-05-12 |
2001-11-22 |
Amgen Inc. |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
AU2011253690C1
(en)
*
|
2000-12-12 |
2018-01-18 |
Board Of Regents, The University Of Texas System |
Molecules with extended half-lives, compositions and uses thereof
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
AU2008201419C1
(en)
*
|
2000-12-12 |
2018-01-18 |
Board Of Regents, The University Of Texas System |
Molecules with extended half-lives, compositions and uses thereof
|
DK1355919T3
(en)
|
2000-12-12 |
2011-03-14 |
Medimmune Llc |
Molecules with longer half-lives, compositions and uses thereof
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
MXPA03010210A
(en)
|
2001-05-11 |
2004-03-10 |
Amgen Inc |
Peptides and related molecules that bind to tall-1.
|
US7332474B2
(en)
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
CA2485373A1
(en)
|
2002-05-10 |
2003-11-20 |
Medimmune, Inc. |
Epha2 monoclonal antibodies and methods of use thereof
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
AU2003263964C1
(en)
|
2002-07-31 |
2010-08-19 |
Seagen Inc. |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20040136992A1
(en)
|
2002-08-28 |
2004-07-15 |
Burton Paul B. J. |
Compositions and method for treating cardiovascular disease
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217798B2
(en)
|
2003-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of Fc-fusion protein serum half-lives by mutagenesis
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
JP4685764B2
(en)
*
|
2003-04-10 |
2011-05-18 |
アボット バイオセラピューティクス コーポレイション |
Modification of antibody FcRn binding affinity or serum half-life by mutagenesis
|
KR20120035234A
(en)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
Recombinant il-9 antibodies and uses thereof
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
EP2298347B1
(en)
|
2003-05-06 |
2015-09-30 |
Biogen Hemophilia Inc. |
Clotting factor chimeric proteins for treatment of a hemostatic disorder
|
JP2007500132A
(en)
|
2003-07-25 |
2007-01-11 |
アムジェン インコーポレイテッド |
LDCAM antagonists and agonists and methods of use thereof
|
CN1871259A
(en)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
Improved antibodies having altered effector function and methods for making the same
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
WO2005044188A2
(en)
|
2003-10-27 |
2005-05-19 |
Amgen Inc. |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
SI1725249T1
(en)
|
2003-11-06 |
2014-04-30 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
CN103212084B
(en)
|
2003-11-13 |
2018-07-13 |
韩美科学株式会社 |
Contain pharmaceutical composition of the immunoglobulin FC region as carrier
|
KR101135244B1
(en)
|
2007-11-29 |
2012-04-24 |
한미사이언스 주식회사 |
A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
PT2311873T
(en)
|
2004-01-07 |
2018-11-20 |
Novartis Vaccines & Diagnostics Inc |
M-csf-specific monoclonal antibody and uses thereof
|
WO2005070967A2
(en)
|
2004-01-22 |
2005-08-04 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
JP2008504012A
(en)
|
2004-01-28 |
2008-02-14 |
シントニックス・ファーマシューティカルズ・インコーポレーテッド |
Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion protein for infertility treatment
|
WO2005110474A2
(en)
|
2004-05-10 |
2005-11-24 |
Macrogenics, Inc. |
HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
ES2605792T3
(en)
|
2004-05-13 |
2017-03-16 |
Icos Corporation |
Quinazolinone used as a human phosphatidylinositol 3-kinase delta inhibitor
|
MXPA06014684A
(en)
|
2004-06-18 |
2007-02-12 |
Ambrx Inc |
Novel antigen-binding polypeptides and their uses.
|
EP1773400A2
(en)
|
2004-07-08 |
2007-04-18 |
Amgen Inc. |
Therapeutic peptides
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
RS20070027A
(en)
|
2004-07-26 |
2008-11-28 |
Biogen Idec Ma Inc., |
Anti-cd154 antibodies
|
CA2573192C
(en)
|
2004-08-04 |
2013-09-10 |
Applied Molecular Evolution Inc. |
Variant fc regions
|
AU2005286770A1
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
CA2586909A1
(en)
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
EP2845865A1
(en)
|
2004-11-12 |
2015-03-11 |
Xencor Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
DE602006003695D1
(en)
|
2005-01-05 |
2009-01-02 |
F Star Biotech Forsch & Entw |
Synthetic immunoglobulin domains with modified binding properties in regions of the molecule other than the complementarity determining regions
|
KR100754667B1
(en)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP1868650B1
(en)
|
2005-04-15 |
2018-10-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
EP2301969B1
(en)
|
2005-05-06 |
2015-12-23 |
ZymoGenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
SI2314623T1
(en)
|
2005-06-21 |
2012-11-30 |
Xoma Technology Ltd |
IL-1beta binding antibodies and fragments thereof
|
KR20080025174A
(en)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
Antibody formulations having optimized aggregation and fragmentation profiles
|
EP3498289A1
(en)
|
2005-07-07 |
2019-06-19 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
CA2616005C
(en)
|
2005-07-18 |
2015-09-22 |
Seattle Genetics, Inc. |
Beta-glucuronide-linker drug conjugates
|
EP2311876A3
(en)
|
2005-07-28 |
2011-04-27 |
Novartis AG |
M-CSF-specific monoclonal antibody and uses thereof
|
ES2526811T3
(en)
|
2005-08-10 |
2015-01-15 |
Macrogenics, Inc. |
Identification and modification of antibodies with Fc regions variants and methods of use of these
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
CA2626082C
(en)
|
2005-10-13 |
2017-04-11 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
TW200732350A
(en)
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
EP2567973B1
(en)
|
2005-11-28 |
2014-05-14 |
Zymogenetics, Inc. |
IL-21 antagonists
|
AU2006326937B2
(en)
|
2005-12-20 |
2012-01-19 |
Cephalon Australia Pty Ltd |
Anti-inflammatory dAb
|
US9012605B2
(en)
|
2006-01-23 |
2015-04-21 |
Amgen Inc. |
Crystalline polypeptides
|
WO2007087673A1
(en)
|
2006-02-01 |
2007-08-09 |
Arana Therapeutics Limited |
Domain antibody construct
|
JP2009529915A
(en)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
Human antibodies and methods specific for gastrin substances
|
JP5624276B2
(en)
|
2006-03-31 |
2014-11-12 |
中外製薬株式会社 |
Methods for controlling blood kinetics of antibodies
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
TWI395754B
(en)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
Humanized c-kit antibody
|
AU2007244683A1
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
US7786270B2
(en)
|
2006-05-26 |
2010-08-31 |
Macrogenics, Inc. |
Humanized FcγRIIB-specific antibodies and methods of use thereof
|
SG177907A1
(en)
|
2006-06-14 |
2012-02-28 |
Macrogenics Inc |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
US7932055B2
(en)
|
2006-06-22 |
2011-04-26 |
Novo Nordisk A/S |
Soluble heterodimeric CD94/NKG2 receptors fusion proteins
|
CA2656224C
(en)
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
JP5764290B2
(en)
|
2006-06-26 |
2015-08-19 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB specific antibodies and methods of use thereof
|
EP2037928B1
(en)
|
2006-06-26 |
2012-01-11 |
Amgen Inc. |
Methods for treating atherosclerosis
|
AT503902B1
(en)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
METHOD FOR MANIPULATING IMMUNE LOBULINS
|
AT503861B1
(en)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
METHOD FOR MANIPULATING T-CELL RECEPTORS
|
AT503889B1
(en)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
MULTIVALENT IMMUNE LOBULINE
|
ES2746925T3
(en)
|
2006-08-03 |
2020-03-09 |
Medimmune Ltd |
Antibodies Directed Towards alfaVbeta6 and Use of Them
|
CL2007002225A1
(en)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
|
WO2008019290A2
(en)
|
2006-08-04 |
2008-02-14 |
Astrazeneca Ab |
Human antibodies to erbb 2
|
CN101626783A
(en)
|
2006-08-04 |
2010-01-13 |
诺华有限公司 |
EPHB3-specific antibody and its application
|
ES2457072T3
(en)
|
2006-08-14 |
2014-04-24 |
Xencor, Inc. |
Optimized antibodies that select as target CD19
|
EP2059535B1
(en)
|
2006-08-18 |
2013-11-06 |
Novartis AG |
Prlr-specific antibody and uses thereof
|
MX2009002151A
(en)
|
2006-08-28 |
2009-07-03 |
Kirin Pharma Kk |
Antagonistic human light-specific human monoclonal antibodies.
|
ES2519375T3
(en)
|
2006-09-01 |
2014-11-06 |
Zymogenetics, Inc. |
IL-31 monoclonal antibodies and use procedures
|
CA2660795C
(en)
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
US20100143254A1
(en)
|
2006-10-16 |
2010-06-10 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
US7825093B2
(en)
|
2006-10-25 |
2010-11-02 |
Amgen Inc. |
Methods of using OSK1 peptide analogs
|
HU0700534D0
(en)
|
2006-11-24 |
2007-10-29 |
Mezoegazdasagi Biotechnologiai |
Transgenic animal with enhanced immune response and method for the preparation thereof
|
PL2099823T5
(en)
|
2006-12-01 |
2023-02-20 |
Seagen Inc. |
Variant target binding agents and uses thereof
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
AU2007333635B2
(en)
|
2006-12-20 |
2014-02-20 |
Xoma (Us) Llc |
Treatment of IL-1-beta related diseases
|
JP2008169195A
(en)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
Insulinotopic peptide drug combo using carrier material
|
EP2077859A4
(en)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
Antibody formulation
|
ES2540807T3
(en)
|
2007-05-04 |
2015-07-13 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Variable domains of rabbit antibodies modified by genetic engineering and uses thereof
|
PT2160401E
(en)
|
2007-05-11 |
2014-10-30 |
Altor Bioscience Corp |
Fusion molecules and il-15 variants
|
NO3072525T3
(en)
|
2007-05-14 |
2018-06-30 |
|
|
CA2687141C
(en)
|
2007-05-22 |
2014-04-01 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
ES2659517T3
(en)
|
2007-05-30 |
2018-03-16 |
Xencor, Inc. |
Methods and compositions for inhibiting cells expressing CD32B
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
ES2627223T3
(en)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentation of binding agents
|
WO2009014708A2
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
DK2181190T3
(en)
|
2007-07-26 |
2014-03-31 |
Amgen Inc |
Modified lecithin-cholesterol acyltransferase enzymes
|
CN101952312A
(en)
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
Multispecific epitope binding proteins and uses thereof
|
PE20140196A1
(en)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
ANTI-CD37 ANTIBODIES
|
NO2195023T3
(en)
|
2007-08-29 |
2018-08-04 |
|
|
EP3689912A1
(en)
|
2007-09-26 |
2020-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
ES2622460T3
(en)
|
2007-09-26 |
2017-07-06 |
Ucb Biopharma Sprl |
Fusions of antibodies with double specificity
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
AU2008333131B2
(en)
|
2007-12-07 |
2013-10-24 |
Merck Serono S/A |
Humanized antibody molecules specific for IL-31
|
DK2217268T3
(en)
|
2007-12-07 |
2016-08-15 |
Zymogenetics Inc |
MONOCLONAL ANTI-HUMAN IL-21 ANTIBODIES
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
MX2010006823A
(en)
|
2007-12-20 |
2010-09-30 |
Xoma Technology Ltd |
Methods for the treatment of gout.
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
EP3575317A1
(en)
|
2007-12-26 |
2019-12-04 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
MX2010007767A
(en)
|
2008-01-18 |
2010-08-09 |
Medimmune Llc |
Cysteine engineered antibodies for site-specific conjugation.
|
US8609105B2
(en)
|
2008-03-18 |
2013-12-17 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
ES2589912T3
(en)
|
2008-04-02 |
2016-11-17 |
Macrogenics, Inc. |
Specific antibodies for the BCR complex and procedures for their use
|
PL2247304T3
(en)
|
2008-04-02 |
2017-01-31 |
Macrogenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
TWI564021B
(en)
|
2008-04-11 |
2017-01-01 |
Chugai Pharmaceutical Co Ltd |
Repeated binding of antigen to antigen binding molecules
|
WO2009131702A2
(en)
*
|
2008-04-25 |
2009-10-29 |
Dyax Corp. |
Antibodies against fcrn and use thereof
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
JOP20190083A1
(en)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
Fgf21 mutant fusion polypeptides and uses thereof
|
EP2671891A3
(en)
|
2008-06-27 |
2014-03-05 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
MX356218B
(en)
|
2008-08-05 |
2018-05-18 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5.
|
JP5611210B2
(en)
|
2008-09-07 |
2014-10-22 |
グリコネックス インコーポレイテッド |
Anti-expanded type I glycosphingolipid antibodies, derivatives and uses thereof
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
CN110317272A
(en)
*
|
2008-10-14 |
2019-10-11 |
霍夫曼-拉罗奇有限公司 |
Immunoglobulin variants and application thereof
|
BRPI0921845A2
(en)
|
2008-11-12 |
2019-09-17 |
Medimmune Llc |
stable sterile aqueous formulation, pharmaceutical unit dosage form, pre-filled syringe, and methods for treating a disease or disorder, treating or preventing rejection, depleting unique expressing t cells in a human patient, and disrupting central germinal architecture in a secondary lymphoid organ of a primate
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
CN104042618B
(en)
|
2008-11-13 |
2018-02-16 |
吉利德卡利斯托加公司 |
The treatment of malignant hematologic disease
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP3385279B1
(en)
|
2009-03-20 |
2020-02-26 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
AU2010229968A1
(en)
|
2009-03-24 |
2011-10-13 |
Gilead Calistoga Llc |
Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
|
EA201101507A1
(en)
|
2009-04-20 |
2012-05-30 |
Гилеад Калистога Ллс. |
METHODS OF TREATMENT OF SOLID TUMORS
|
CN106188295A
(en)
|
2009-04-20 |
2016-12-07 |
牛津生物疗法有限公司 |
It is specific to the antibody of cadherins 17
|
CA2759333A1
(en)
|
2009-04-22 |
2010-10-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
US20120052069A1
(en)
|
2009-05-05 |
2012-03-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
SG10201402038WA
(en)
|
2009-05-05 |
2014-07-30 |
Amgen Inc |
FGF21 Mutants And Uses Thereof
|
ES2548030T3
(en)
|
2009-06-01 |
2015-10-13 |
Medimmune, Llc |
Molecules with prolonged half-lives and uses thereof
|
EP2443137B1
(en)
|
2009-06-15 |
2015-05-20 |
Biokine Therapeutics Ltd. |
Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
|
EP2442824A2
(en)
|
2009-06-19 |
2012-04-25 |
MedImmune, LLC |
Protease variants
|
EP2711018A1
(en)
|
2009-06-22 |
2014-03-26 |
MedImmune, LLC |
Engineered Fc regions for site-specific conjugation
|
EP2456443A1
(en)
|
2009-07-21 |
2012-05-30 |
Gilead Calistoga LLC |
Treatment of liver disorders with pi3k inhibitors
|
US8840889B2
(en)
|
2009-08-13 |
2014-09-23 |
The Johns Hopkins University |
Methods of modulating immune function
|
CA2770737C
(en)
|
2009-08-13 |
2020-05-12 |
Crucell Holland B.V. |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
SI2486141T1
(en)
|
2009-10-07 |
2018-06-29 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
WO2011056073A2
(en)
|
2009-11-04 |
2011-05-12 |
Erasmus University Medical Center Rotterdam |
Novel compounds for modulating neovascularisation and methods of treatment using these compounds
|
MX2012005864A
(en)
|
2009-11-20 |
2012-08-31 |
Amgen Inc |
Anti-orai1 antigen binding proteins and uses thereof.
|
MX343747B
(en)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Targeted binding agents against b7-h1.
|
UA109888C2
(en)
|
2009-12-07 |
2015-10-26 |
|
ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
|
KR101312829B1
(en)
|
2009-12-30 |
2013-09-27 |
한화엘앤씨 주식회사 |
Transgenic pig expressing HO-1 and TNFR1-Fc and the method of producing thereof
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
NZ701539A
(en)
|
2010-03-04 |
2015-04-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
AR081066A1
(en)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
|
AR081755A1
(en)
|
2010-04-02 |
2012-10-17 |
Hanmi Holdings Co Ltd |
FORMULATION OF PROLONGED ACTION OF THE FOLICULES STIMULATING HORMONE WHERE AN IMMUNOGLOBULIN FRAGMENT, PREPARATION METHOD AND METHOD TO TREAT A SUBJECT SUFFERING A REPRODUCTIVE DISORDER ARE USED
|
AR080993A1
(en)
|
2010-04-02 |
2012-05-30 |
Hanmi Holdings Co Ltd |
FORMULATION OF PROLONGED BETA INTERFERTION ACTION WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
|
EP2556086B1
(en)
|
2010-04-09 |
2015-03-04 |
Amgen Inc. |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
MX2012011986A
(en)
|
2010-04-15 |
2013-03-05 |
Amgen Inc |
Human fgf receptor and î²-klotho binding proteins.
|
BR112012028326A2
(en)
|
2010-05-06 |
2017-03-21 |
Novartis Ag |
isolated multivalent antibody, isolated biparatopic antibodies, nucleic acid, vector, pharmaceutical composition, method of obtaining said antibodies and use thereof
|
US9428583B2
(en)
|
2010-05-06 |
2016-08-30 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
BR112012030179A8
(en)
|
2010-05-27 |
2023-03-14 |
Merck Sharp & Dohme |
FC CONTAINING POLYPEPTIDE
|
CN103140237A
(en)
|
2010-07-09 |
2013-06-05 |
比奥根艾迪克依蒙菲利亚公司 |
Factor ix polypeptides and methods of use thereof
|
NZ703035A
(en)
|
2010-07-09 |
2016-06-24 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
KR101382593B1
(en)
|
2010-07-21 |
2014-04-10 |
한미사이언스 주식회사 |
Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
|
MX339622B
(en)
|
2010-08-02 |
2016-06-02 |
Macrogenics Inc |
Covalent diabodies and uses thereof.
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
ME02637B
(en)
|
2010-08-20 |
2017-06-20 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
SG10201506782XA
(en)
|
2010-08-27 |
2015-10-29 |
Stem Centrx Inc |
Notum protein modulators and methods of use
|
CN106620693A
(en)
|
2010-09-03 |
2017-05-10 |
艾伯维施特姆森特克斯有限责任公司 |
Novel modulators and methods of use
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
JP6251570B2
(en)
|
2010-09-21 |
2017-12-20 |
アルター・バイオサイエンス・コーポレーション |
Multimeric IL-15 soluble fusion molecule and methods for its production and use
|
JP6159660B2
(en)
|
2010-09-22 |
2017-07-05 |
アムジエン・インコーポレーテツド |
Immunoglobulins as carriers and uses thereof
|
UA112062C2
(en)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
CD33-Binding Agent
|
RS59589B1
(en)
|
2010-11-05 |
2019-12-31 |
Zymeworks Inc |
Stable heterodimeric antibody design with mutations in the fc domain
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
MX365235B
(en)
|
2010-11-30 |
2019-05-28 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly.
|
RU2592672C9
(en)
|
2010-12-08 |
2016-11-27 |
СтемСентРкс, Инк. |
Novel modulators and methods for use thereof
|
PT2654790T
(en)
|
2010-12-22 |
2019-05-16 |
Teva Pharmaceuticals Australia Pty Ltd |
Modified antibody with improved half-life
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
KR101276801B1
(en)
|
2011-01-21 |
2013-06-19 |
한화엘앤씨 주식회사 |
Transgenic pig expressing sTNFR1-Fc and use thereof
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
SA112330278B1
(en)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
Novel modulators and methods of use
|
US20140093496A1
(en)
|
2011-02-25 |
2014-04-03 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
|
KR20140145947A
(en)
|
2011-03-16 |
2014-12-24 |
암젠 인크 |
Potent and selective inhibitors of nav1.3 and nav1.7
|
EP2686014A1
(en)
|
2011-03-16 |
2014-01-22 |
Sanofi |
Uses of a dual v region antibody-like protein
|
KR20160044598A
(en)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
Antibody fc variants
|
EP3415528B1
(en)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
JP6145088B2
(en)
|
2011-05-21 |
2017-06-07 |
マクロジェニクス,インコーポレーテッド |
Deimmunized serum binding domain and its use to extend serum half-life
|
AU2012258907A1
(en)
|
2011-05-25 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
Method for preparing Fc-containing polypeptides having improved properties
|
UA113626C2
(en)
|
2011-06-02 |
2017-02-27 |
|
A COMPOSITION FOR THE TREATMENT OF DIABETES CONTAINING THE DURABLE INSULIN CON conjugate AND THE DUAL ACTION INSULINOTROPIC PIPIDE
|
CN108424451B
(en)
|
2011-06-03 |
2022-09-09 |
佐马技术有限公司 |
Antibodies specific for TGF-beta
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
CA2838503C
(en)
|
2011-06-10 |
2020-02-18 |
Hanmi Science Co., Ltd. |
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
PH12018501119A1
(en)
|
2011-06-17 |
2019-02-04 |
Hanmi Science Co Ltd |
A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
|
EP2726508B1
(en)
|
2011-06-28 |
2017-08-09 |
Oxford BioTherapeutics Ltd |
Antibodies to adp-ribosyl cyclase 2
|
JP2014520869A
(en)
|
2011-07-18 |
2014-08-25 |
アルツ バイオロジクス アクティーゼルスカブ |
Luteinizing hormone (LH) compounds with long-acting and biological activity
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
JP6284478B2
(en)
|
2011-09-05 |
2018-02-28 |
ハンミ サイエンス カンパニー リミテッド |
Pharmaceutical composition for cancer treatment comprising interferon alpha conjugate
|
TWI593708B
(en)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
Fusion proteins for treating metabolic disorders
|
TW201315742A
(en)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
Dual fuction proteins for treating metabolic disorders
|
TW201817745A
(en)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
|
SG11201401101XA
(en)
|
2011-09-30 |
2014-08-28 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule for promoting loss of antigens
|
EP2760471B9
(en)
|
2011-09-30 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
EP2773667A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
EP2773664A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
WO2013067055A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
EP2773665A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
CN104080811B
(en)
|
2011-11-04 |
2019-09-27 |
酵活有限公司 |
There is the antibody design of the stabilization heterodimeric of mutation in Fc structural domain
|
KR20130049671A
(en)
|
2011-11-04 |
2013-05-14 |
한미사이언스 주식회사 |
Method for preparation of biological active polypeptide conjugate
|
TW201323442A
(en)
|
2011-11-04 |
2013-06-16 |
Novartis Ag |
Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
|
WO2013068571A1
(en)
|
2011-11-11 |
2013-05-16 |
Ucb Pharma S.A. |
Albumin binding antibodies and binding fragments thereof
|
BR112014012609A2
(en)
|
2011-11-17 |
2020-10-20 |
Pfizer Inc |
cytotoxic and conjugated antibody drug peptides thereof
|
US20150056182A1
(en)
|
2011-11-30 |
2015-02-26 |
Chugai Seiyaku Kabushiki Kaisha |
Drug containing carrier into cell for forming immune complex
|
TW201328707A
(en)
|
2011-12-05 |
2013-07-16 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3
|
CN104159924B
(en)
|
2011-12-05 |
2018-03-16 |
诺华股份有限公司 |
The antibody of EGF-R ELISA 3 (HER3)
|
WO2013096516A1
(en)
|
2011-12-19 |
2013-06-27 |
Xoma Technology Ltd. |
Methods for treating acne
|
CN106831985A
(en)
|
2011-12-21 |
2017-06-13 |
诺华股份有限公司 |
The composition and method of the P factors are targeted for antibody
|
CA2859755C
(en)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
KR101895047B1
(en)
|
2011-12-30 |
2018-09-06 |
한미사이언스 주식회사 |
A site-specific GLP-2 conjugate using an immunoglobulin fragment
|
JP2015509091A
(en)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
Humanized antibody
|
WO2013106485A2
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
WO2013126746A2
(en)
|
2012-02-24 |
2013-08-29 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
TW202015731A
(en)
|
2012-02-24 |
2020-05-01 |
日商中外製藥股份有限公司 |
Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc[gamma]RIIB
|
EA201691327A1
(en)
|
2012-03-05 |
2017-03-31 |
Джилид Калистога Ллс |
POLYMORPHIC FORMS (S) -2- (1- (9H-PURIN-6-ILAMINO) PROPYL) -5-FTOR-3-PHENYL-CHINAZOLIN-4 (3H) -OH
|
AR090281A1
(en)
|
2012-03-08 |
2014-10-29 |
Hanmi Science Co Ltd |
IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
|
KR101665009B1
(en)
|
2012-03-09 |
2016-10-11 |
한미사이언스 주식회사 |
Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
US10064951B2
(en)
|
2012-03-30 |
2018-09-04 |
Hanmi Science Co., Ltd. |
Liquid formulation of highly concentrated long-acting human growth hormone conjugate
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
CA2872540A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
GB201208370D0
(en)
*
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
JP6423340B2
(en)
|
2012-05-15 |
2018-11-14 |
シアトル ジェネティクス,インコーポレイティド |
Self-stabilizing linker conjugate
|
CN104335047B
(en)
*
|
2012-05-23 |
2017-08-15 |
弗·哈夫曼-拉罗切有限公司 |
The system of selection of therapeutic agent
|
CA2874721A1
(en)
|
2012-05-30 |
2013-12-05 |
Tomoyuki Igawa |
Target tissue-specific antigen-binding molecule
|
DK2857419T3
(en)
|
2012-05-30 |
2021-03-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule for the elimination of aggregated antigens
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
HRP20211641T1
(en)
|
2012-07-13 |
2022-02-04 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
EP2875046B1
(en)
|
2012-07-19 |
2020-02-26 |
Amgen Inc. |
Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
|
AR091902A1
(en)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
LIQUID FORMULATION OF A PROLONGED INSULIN CONJUGATE
|
AR092862A1
(en)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD
|
KR101968344B1
(en)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
A composition for treating hyperlipidemia comprising oxyntomodulin analog
|
NZ630363A
(en)
|
2012-07-25 |
2018-09-28 |
Celldex Therapeutics Inc |
Anti-kit antibodies and uses thereof
|
MX371442B
(en)
|
2012-08-24 |
2020-01-30 |
Chugai Pharmaceutical Co Ltd |
Fcyriib-specific fc region variant.
|
SG11201502757QA
(en)
|
2012-10-09 |
2015-05-28 |
Igenica Biotherapeutics Inc |
Anti-c16orf54 antibodies and methods of use thereof
|
KR101762047B1
(en)
|
2012-11-05 |
2017-07-27 |
화이자 인코포레이티드 |
Spliceostatin analogs
|
KR101993393B1
(en)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
A composition for treating diabetes or diabesity comprising oxyntomodulin analog
|
EA031852B1
(en)
|
2012-11-06 |
2019-03-29 |
Ханми Фарм. Ко., Лтд. |
Liquid formulation of protein conjugate comprising an oxyntomodulin and an immunoglobulin fragment
|
EP2917240A1
(en)
|
2012-11-07 |
2015-09-16 |
Pfizer Inc. |
Anti-notch3 antibodies and antibody-drug conjugates
|
UY35144A
(en)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
MX368067B
(en)
|
2012-12-05 |
2019-09-18 |
Novartis Ag |
Compositions and methods for antibodies targeting epo.
|
CN105051064A
(en)
|
2013-01-24 |
2015-11-11 |
葛兰素史克知识产权开发有限公司 |
Tnf-alpha antigen-binding proteins
|
KR102073748B1
(en)
|
2013-01-31 |
2020-02-05 |
한미약품 주식회사 |
Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same
|
US10065987B2
(en)
|
2013-02-12 |
2018-09-04 |
Bristol-Myers Squibb Company |
High pH protein refolding methods
|
EP3744728A1
(en)
|
2013-02-12 |
2020-12-02 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
CN105164159A
(en)
|
2013-02-22 |
2015-12-16 |
施特姆森特克斯股份有限公司 |
Novel antibody conjugates and uses thereof
|
PT2963055T
(en)
|
2013-02-26 |
2019-07-25 |
Hanmi Pharm Ind Co Ltd |
Site-specific insulin conjugate
|
PE20191481A1
(en)
|
2013-02-26 |
2019-10-18 |
Hanmi Pharm Ind Co Ltd |
NEW INSULIN ANALOGUE AND ITS USE
|
TWI647240B
(en)
|
2013-03-05 |
2019-01-11 |
韓美藥品股份有限公司 |
Improved process for preparing physiologically active polypeptide complexes in high yield
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
WO2014136114A1
(en)
|
2013-03-06 |
2014-09-12 |
Protalix Ltd. |
TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
|
US10087232B2
(en)
|
2013-03-06 |
2018-10-02 |
Protalix Ltd. |
Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy
|
EP2970408B1
(en)
|
2013-03-12 |
2018-01-10 |
Amgen Inc. |
Potent and selective inhibitors of nav1.7
|
EP3431592A1
(en)
|
2013-03-14 |
2019-01-23 |
Translate Bio, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
JP2016514130A
(en)
|
2013-03-14 |
2016-05-19 |
ノバルティス アーゲー |
Antibody against Notch3
|
LT2968520T
(en)
|
2013-03-14 |
2021-09-27 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
|
EP2968440B1
(en)
|
2013-03-15 |
2019-06-05 |
Zymeworks Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
BR112015023084A2
(en)
|
2013-03-15 |
2017-11-21 |
Abbvie Biotechnology Ltd |
monoclonal anti-cd25 antibody or anti-cd25 binding fragment of a monoclonal antibody, antibody-drug conjugate, pharmaceutical composition, nucleic acid, vector, prokaryotic and eukaryotic host cell, method for producing an anti-cd25 antibody or binding fragment anti-cd25, and use of a monoclonal anti-cd25 antibody from an antibody-drug conjugate or pharmaceutical composition
|
MX2015012563A
(en)
|
2013-03-15 |
2016-10-26 |
Abbvie Biotechnology Ltd |
Anti-cd25 antibodies and their uses.
|
JP6397886B2
(en)
|
2013-03-15 |
2018-09-26 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Therapeutic peptide
|
US20140377253A1
(en)
|
2013-03-15 |
2014-12-25 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
US20160051673A1
(en)
|
2013-03-29 |
2016-02-25 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
|
EP3783017A1
(en)
|
2013-04-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
KR101895634B1
(en)
|
2013-05-31 |
2018-09-05 |
한미약품 주식회사 |
IgG4 Fc fragment comprising modified hinge region
|
US10100123B2
(en)
|
2013-06-06 |
2018-10-16 |
Pierre Fabre Medicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014200349A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceutical B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
AR096601A1
(en)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
|
UY35620A
(en)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
|
AR096891A1
(en)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
|
AR096890A1
(en)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
CONJUGATING FC OF IMMUNOGLOBULINA, THAT MAINTAINS THE UNION AFFINITY OF THE FC FRAGMENT OF THE IMMUNOGLOBULIN TO FCRN
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CN111518199A
(en)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
Humanized antibodies with ultralong complementarity determining regions
|
US9340582B2
(en)
|
2013-07-25 |
2016-05-17 |
Novartis Ag |
Bioconjugates of synthetic apelin polypeptides
|
MX2016001020A
(en)
|
2013-07-25 |
2016-08-03 |
Novartis Ag |
Cyclic polypeptides for the treatment of heart failure.
|
WO2015017529A2
(en)
|
2013-07-31 |
2015-02-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
UA116479C2
(en)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
KR20160054501A
(en)
|
2013-08-26 |
2016-05-16 |
맵백스 테라퓨틱스, 인코포레이티드 |
Nucleic acids encoding human antibodies to sialyl-lewis a
|
CN105848671B
(en)
|
2013-08-28 |
2019-12-13 |
艾伯维施特姆森特克斯有限责任公司 |
Site-specific antibody conjugation methods and compositions
|
KR20160046914A
(en)
|
2013-08-28 |
2016-04-29 |
스템센트알엑스 인코포레이티드 |
Novel sez6 modulators and methods of use
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
BR112016006455A2
(en)
|
2013-09-27 |
2017-08-01 |
Hanmi Pharm Ind Co Ltd |
? long-acting human growth hormone conjugate formulation?
|
CA2921707C
(en)
|
2013-10-15 |
2023-03-28 |
Seattle Genetics, Inc. |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
EP3057605A1
(en)
|
2013-10-18 |
2016-08-24 |
Novartis AG |
Methods of treating diabetes and related disorders
|
PE20160870A1
(en)
|
2013-11-06 |
2016-09-09 |
Abbvie Stemcentrx Llc |
NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE
|
EP3094973B1
(en)
|
2013-11-07 |
2020-07-29 |
Diagnodus Limited |
Biomarkers
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
BR112016012358A2
(en)
|
2013-12-06 |
2017-09-26 |
Dana Farber Cancer Inst Inc |
therapeutic peptides
|
TWI777502B
(en)
|
2013-12-19 |
2022-09-11 |
美商西雅圖遺傳學公司 |
Methylene carbamate linkers for use with targeted-drug conjugates
|
EP3083623A1
(en)
|
2013-12-20 |
2016-10-26 |
Gilead Calistoga LLC |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
NZ736970A
(en)
|
2013-12-20 |
2018-11-30 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
MX368804B
(en)
|
2013-12-24 |
2019-10-17 |
Univ Texas |
FCRN ANTAGONISTS and METHODS OF USE.
|
EP3086815B1
(en)
|
2013-12-27 |
2022-02-09 |
Zymeworks Inc. |
Sulfonamide-containing linkage systems for drug conjugates
|
CN110903398B
(en)
*
|
2014-01-15 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
Fc region variants with modified FCRN and maintained protein A binding properties
|
PE20161153A1
(en)
|
2014-01-20 |
2016-10-27 |
Hanmi Pharm Ind Co Ltd |
LONG-ACTING INSULIN AND USE OF THE SAME
|
US9738716B2
(en)
|
2014-01-24 |
2017-08-22 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho binding proteins and methods of use thereof
|
PT3099692T
(en)
|
2014-01-27 |
2019-05-24 |
Pfizer |
Bifunctional cytotoxic agents
|
KR20240036143A
(en)
|
2014-02-17 |
2024-03-19 |
씨젠 인크. |
Hydrophilic antibody-drug conjugates
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
CA2939006A1
(en)
|
2014-03-14 |
2015-09-17 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
WO2015152618A1
(en)
|
2014-03-31 |
2015-10-08 |
한미약품 주식회사 |
Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
|
MX2016012873A
(en)
|
2014-04-04 |
2017-03-07 |
Bionomics Inc |
Humanized antibodies that bind lgr5.
|
ES2913205T3
(en)
|
2014-05-13 |
2022-06-01 |
Bioatla Inc |
Conditionally active biological proteins
|
US20170267780A1
(en)
|
2014-05-16 |
2017-09-21 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
PL3148579T3
(en)
|
2014-05-28 |
2021-07-19 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
AR100639A1
(en)
|
2014-05-29 |
2016-10-19 |
Hanmi Pharm Ind Co Ltd |
COMPOSITION TO TREAT DIABETES THAT INCLUDES CONJUGATES OF PROLONGED INSULIN ANALOGS AND CONJUGATES OF PROLONGED INSULINOTROPIC PEPTIDES
|
TWI684458B
(en)
|
2014-05-30 |
2020-02-11 |
南韓商韓美藥品股份有限公司 |
Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
|
WO2015187811A2
(en)
|
2014-06-04 |
2015-12-10 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside gd2
|
KR20150140177A
(en)
|
2014-06-05 |
2015-12-15 |
한미약품 주식회사 |
Method of decreasing immunogenicity of protein and pepteide
|
SI3151921T1
(en)
|
2014-06-06 |
2019-12-31 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CA2951391C
(en)
|
2014-06-10 |
2021-11-02 |
Amgen Inc. |
Apelin polypeptides
|
AU2015274696B2
(en)
|
2014-06-13 |
2018-09-27 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
WO2015200080A1
(en)
|
2014-06-23 |
2015-12-30 |
Novartis Ag |
Site specific protein modifications
|
EP3673915A1
(en)
|
2014-06-30 |
2020-07-01 |
Altor BioScience Corporation |
Il-15-based molecules and methods of use thereof
|
PE20170287A1
(en)
|
2014-08-07 |
2017-04-05 |
Novartis Ag |
ANTI-PROTEIN ANTIBODIES SIMILAR TO ANGIOPOYETIN 4 AND METHODS OF USE
|
EP3194437B1
(en)
|
2014-08-07 |
2021-01-20 |
Novartis AG |
Angiopoietin-like 4 (angptl4) antibodies and methods of use
|
WO2016036916A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
SG11201701423RA
(en)
|
2014-09-03 |
2017-03-30 |
Boehringer Ingelheim Int |
Compound targeting il-23a and tnf-alpha and uses thereof
|
TW201617368A
(en)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
Novel anti-MFI2 antibodies and methods of use
|
MX2017003247A
(en)
|
2014-09-15 |
2017-11-30 |
Amgen Inc |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof.
|
TWI802396B
(en)
|
2014-09-16 |
2023-05-11 |
南韓商韓美藥品股份有限公司 |
Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
|
EP4029873A1
(en)
|
2014-09-17 |
2022-07-20 |
Zymeworks Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
CN107108721B
(en)
|
2014-09-29 |
2021-09-07 |
杜克大学 |
Bispecific molecules comprising an HIV-1 envelope targeting arm
|
MA41044A
(en)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
|
DK3221346T3
(en)
|
2014-11-21 |
2020-10-12 |
Bristol Myers Squibb Co |
ANTIBODIES INCLUDING MODIFIED CONSTANT AREAS OF THE HEAVY CHAIN
|
HUE050596T2
(en)
|
2014-11-21 |
2020-12-28 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
GB201421901D0
(en)
|
2014-12-09 |
2015-01-21 |
Cambridge Entpr Ltd |
A method of rational antibody design
|
ES2834739T3
(en)
|
2014-12-11 |
2021-06-18 |
Pf Medicament |
Anti-C10orf54 antibodies and their uses
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
CA2963760A1
(en)
|
2014-12-19 |
2016-06-23 |
Yoshinao Ruike |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
UY36449A
(en)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
|
EP3237450B1
(en)
|
2014-12-22 |
2021-03-03 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
AU2015369683C1
(en)
|
2014-12-23 |
2024-06-20 |
Bristol-Myers Squibb Company |
Antibodies to TIGIT
|
PE20171154A1
(en)
|
2014-12-30 |
2017-08-16 |
Hanmi Pharm Ind Co Ltd |
GLUCAGON DERIVATIVES WITH IMPROVED STABILITY
|
KR102418477B1
(en)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
Gluagon Derivatives
|
GB2557389B
(en)
|
2015-01-14 |
2020-12-23 |
Brigham & Womens Hospital Inc |
Treatment of cancer with anti-lap monoclonal antibodies
|
WO2016123454A1
(en)
|
2015-01-29 |
2016-08-04 |
Board Of Trustees Of Miching State University |
Cryptic polypeptides and uses thereof
|
EA201791754A1
(en)
|
2015-02-05 |
2019-01-31 |
Чугаи Сейяку Кабусики Кайся |
ANTIBODIES CONTAINING ANTIGEN-BINDING DOMAIN DEPENDING ON THE CONCENTRATION OF IONS, Fc-AREA OPTIONS, IL-8-CONNECTING ANTIBODIES AND THEIR APPLICATIONS
|
EP3260139A4
(en)
|
2015-02-17 |
2018-09-05 |
Hanmi Pharm. Co., Ltd. |
Long-acting insulin or insulin analogue complex
|
EP3265491A1
(en)
|
2015-03-03 |
2018-01-10 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
PL3265123T3
(en)
|
2015-03-03 |
2023-03-13 |
Kymab Limited |
Antibodies, uses & methods
|
MX2017012102A
(en)
|
2015-03-20 |
2018-01-12 |
Pfizer |
Bifunctional cytotoxic agents containing the cti pharmacophore.
|
HRP20230060T1
(en)
|
2015-05-29 |
2023-03-17 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
JP2018522540A
(en)
|
2015-06-05 |
2018-08-16 |
ノバルティス アーゲー |
Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
|
JOP20200312A1
(en)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
Factor xi antibodies and methods of use
|
BR112017028353A2
(en)
|
2015-06-29 |
2018-09-04 |
The Rockfeller University |
cd40 antibodies with enhanced agonist activity
|
MX2017016845A
(en)
|
2015-06-30 |
2018-08-01 |
Hanmi Pharm Ind Co Ltd |
Glucagon derivative and a composition comprising a long acting conjugate of the same.
|
RU2752530C2
(en)
|
2015-08-03 |
2021-07-29 |
Новартис Аг |
Methods for treating fgf21-related disorders
|
CN108289928A
(en)
|
2015-08-06 |
2018-07-17 |
哈佛大学校长及研究员协会 |
Improved microorganism-binding molecule and its purposes
|
UY36870A
(en)
|
2015-08-28 |
2017-03-31 |
Hanmi Pharm Ind Co Ltd |
NEW INSULIN ANALOGS
|
MX2018002315A
(en)
|
2015-09-01 |
2018-04-11 |
Agenus Inc |
Anti-pd-1 antibodies and methods of use thereof.
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
KR20180042433A
(en)
|
2015-09-09 |
2018-04-25 |
노파르티스 아게 |
Use of thymus substrate lymphopoietin (TSLP) -binding antibodies and antibodies
|
AU2016323440B2
(en)
|
2015-09-15 |
2023-07-13 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
JP7222710B2
(en)
|
2015-09-24 |
2023-02-15 |
ハンミ ファーマシューティカル カンパニー リミテッド |
Protein Conjugates Using Specific Positions of Immunoglobulin Fragments as Linking Sites
|
AR106184A1
(en)
|
2015-09-29 |
2017-12-20 |
Celgene Corp |
PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
|
WO2017058944A1
(en)
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Asgr inhibitors
|
MX2018004041A
(en)
|
2015-10-01 |
2018-11-09 |
Amgen Inc |
Treatment of bile acid disorders.
|
EP3370771A4
(en)
|
2015-11-03 |
2019-06-19 |
Ambrx, Inc. |
Anti-cd3-folate conjugates and their uses
|
JP6486316B2
(en)
|
2015-11-03 |
2019-03-20 |
財團法人工業技術研究院Industrial Technology Research Institute |
Antibody-drug conjugate (ADC) and method for forming the same
|
MX2018006072A
(en)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof.
|
EP3383910A1
(en)
|
2015-11-30 |
2018-10-10 |
AbbVie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
US10188660B2
(en)
|
2015-11-30 |
2019-01-29 |
Abbvie Inc. |
Anti-huLRRC15 antibody drug conjugates and methods for their use
|
US11447557B2
(en)
|
2015-12-02 |
2022-09-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
US10144768B2
(en)
|
2015-12-04 |
2018-12-04 |
Novartis Ag |
Antibody cytokine engrafted compositions and methods of use for immunoregulation
|
MX2018006218A
(en)
|
2015-12-04 |
2018-09-05 |
Seattle Genetics Inc |
Conjugates of quaternized tubulysin compounds.
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
US10822408B2
(en)
|
2015-12-15 |
2020-11-03 |
Amgen Inc. |
PACAP antibodies and uses thereof
|
CR20180365A
(en)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEINS OF UNION TO THE ANTI-TL1A / ANTI-TNF-a BISPECTIVE ANTIGEN AND ITS USES
|
JP2019506844A
(en)
|
2015-12-18 |
2019-03-14 |
ノバルティス アーゲー |
Antibodies targeting CD32b and methods of use thereof
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
CN108699125B
(en)
|
2015-12-31 |
2022-10-28 |
韩美药品株式会社 |
glucagon/GLP-1/GIP receptor triple agonists
|
CN108473569B
(en)
|
2016-01-11 |
2022-11-22 |
苏黎世大学 |
Immunostimulatory humanized monoclonal antibodies against human interleukin-2 and fusion proteins thereof
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
AR107483A1
(en)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
CONJUGATE OF THERAPEUTIC ENZYMES
|
WO2017134547A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
US20190284293A1
(en)
|
2016-03-04 |
2019-09-19 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
EP3423489A1
(en)
|
2016-03-04 |
2019-01-09 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
AR107823A1
(en)
|
2016-03-07 |
2018-06-06 |
Hanmi Pharm Ind Co Ltd |
DERIVATIVES OF POLYETHYLENE GLYCOL AND USE OF THE SAME
|
KR20180127407A
(en)
|
2016-03-16 |
2018-11-28 |
메리맥 파마슈티컬즈, 인크. |
Engineered TRAIL for Cancer Therapy
|
KR20220004226A
(en)
|
2016-03-22 |
2022-01-11 |
바이오노믹스 리미티드 |
Administration of an anti-lgr5 monoclonal antibody
|
UA125510C2
(en)
|
2016-03-25 |
2022-04-13 |
Сіджен Інк. |
Process for the preparation of pegylated drug-linkers and intermediates thereof
|
MA45328A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
KR102673420B1
(en)
|
2016-04-04 |
2024-06-07 |
바이오버라티브 유에스에이 인코포레이티드 |
Anti-complement factor BB antibodies and uses thereof
|
PE20190353A1
(en)
|
2016-04-15 |
2019-03-07 |
Macrogenics Inc |
NOVELTY B7-H3 JOINT MOLECULES, ANTIBODY-DRUG CONJUGATES OF THE SAME AND METHODS OF USE OF THE SAME
|
AU2017254674A1
(en)
|
2016-04-21 |
2018-11-01 |
Abbvie Stemcentrx Llc |
Novel anti-BMPR1B antibodies and methods of use
|
JP7138567B2
(en)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
Antibodies against growth differentiation factor 15 and their uses
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
KR102463844B1
(en)
*
|
2016-05-27 |
2022-11-08 |
알토 바이오사이언스 코포레이션 |
Construction and Characterization of Multimeric IL-15-Based Molecules with CD3 Binding Domains
|
JP7267012B2
(en)
|
2016-05-27 |
2023-05-01 |
アジェナス インコーポレイテッド |
Anti-TIM-3 antibody and method of use thereof
|
EP4371570A3
(en)
|
2016-06-08 |
2024-07-17 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
KR102492057B1
(en)
|
2016-06-15 |
2023-01-26 |
노파르티스 아게 |
Methods of treating diseases using inhibitors of bone morphogenetic protein 6 (BMP6)
|
EP3471762A4
(en)
|
2016-06-16 |
2020-03-11 |
The Board of Trustees of the Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to cd81
|
IL299221A
(en)
|
2016-06-21 |
2023-02-01 |
Teneobio Inc |
Cd3 binding antibodies
|
UA126662C2
(en)
|
2016-06-29 |
2023-01-11 |
Ханмі Фарм. Ко., Лтд. |
Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereofgj[slyt uk.
|
JP2019525772A
(en)
|
2016-07-08 |
2019-09-12 |
スターテン・バイオテクノロジー・ベー・フェー |
Anti-APOC3 antibody and method of use thereof
|
TWI780057B
(en)
|
2016-07-14 |
2022-10-11 |
美商必治妥美雅史谷比公司 |
Antibodies against tim3 and uses thereof
|
AU2017325654A1
(en)
|
2016-08-02 |
2019-02-14 |
Visterra, Inc. |
Engineered polypeptides and uses thereof
|
EP3493853A1
(en)
|
2016-08-03 |
2019-06-12 |
Pfizer Inc |
Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
|
CA3026050A1
(en)
|
2016-08-05 |
2018-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for prophylaxis or treatment of il-8 related diseases
|
EA201990470A1
(en)
|
2016-08-09 |
2019-09-30 |
Сиэтл Дженетикс, Инк. |
MEDICINE CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSICAL AND CHEMICAL PROPERTIES
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
JP7030109B2
(en)
|
2016-09-14 |
2022-03-04 |
テネオバイオ, インコーポレイテッド |
CD3 binding antibody
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
KR102257154B1
(en)
|
2016-09-19 |
2021-05-28 |
셀진 코포레이션 |
Methods of treating immune diseases using PD-1 binding protein
|
KR20180033105A
(en)
|
2016-09-23 |
2018-04-02 |
한미약품 주식회사 |
Insulin analogs with reduced affinity to insulin receptor and use thereof
|
MX2019003683A
(en)
|
2016-10-11 |
2019-08-22 |
Agenus Inc |
Anti-lag-3 antibodies and methods of use thereof.
|
US11638762B2
(en)
|
2016-10-18 |
2023-05-02 |
Seagen Inc. |
Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
|
JP7096240B2
(en)
|
2016-10-19 |
2022-07-05 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
Method for Quantifying Unbound C5 in Sample
|
CA3200275A1
(en)
|
2016-10-21 |
2018-04-26 |
Nantcell, Inc. |
Multimeric il-15-based molecules
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
CA3041340A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
US20230137351A1
(en)
|
2016-11-14 |
2023-05-04 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
CR20190297A
(en)
|
2016-11-23 |
2019-11-01 |
Bioverativ Therapeutics Inc |
Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
JP2019536823A
(en)
|
2016-12-05 |
2019-12-19 |
ハンミ ファーマシューティカル カンパニー リミテッド |
Conjugate with reduced immune response
|
WO2018104893A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
|
JP7106538B2
(en)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
Antibodies and methods of their use
|
MD3551660T2
(en)
|
2016-12-07 |
2024-03-31 |
Agenus Inc |
Anti-CTLA-4 antibodies and methods of use thereof
|
US20190352335A1
(en)
|
2016-12-19 |
2019-11-21 |
Hanmi Pharm. Co., Ltd. |
Brain targeting long-acting protein conjugate
|
WO2018116267A2
(en)
|
2016-12-23 |
2018-06-28 |
Novartis Ag |
Methods of treatment with anti-factor xi/xia antibodies
|
IL308980A
(en)
|
2016-12-23 |
2024-01-01 |
Novartis Ag |
Factor xi antibodies and methods of use
|
CA3049424A1
(en)
|
2017-01-06 |
2018-07-12 |
Avidity Biosciences Llc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
WO2018129451A2
(en)
|
2017-01-09 |
2018-07-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-fgfr antibodies and methods of use
|
AU2018211561B2
(en)
|
2017-01-24 |
2020-04-30 |
Pfizer Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
WO2018143729A1
(en)
|
2017-02-03 |
2018-08-09 |
한미약품 주식회사 |
Conjugate of bioactive material having enhanced sustainability and use thereof
|
CN110545852B
(en)
|
2017-02-07 |
2023-05-26 |
韩美药品株式会社 |
Non-peptide polymer linker compounds, conjugates comprising the same, and methods of making the same
|
US10899844B2
(en)
|
2017-02-08 |
2021-01-26 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
SG11201906947SA
(en)
|
2017-02-17 |
2019-08-27 |
Bristol Myers Squibb Co |
Antibodies to alpha-synuclein and uses thereof
|
US11129883B2
(en)
|
2017-03-06 |
2021-09-28 |
Altor BioScience, LLC. |
IL-15-based fusions to IL-12 and IL-18
|
KR101941975B1
(en)
|
2017-03-17 |
2019-01-25 |
고려대학교 산학협력단 |
Composition for Treating Diabetes Containing ATPIF1
|
AU2018239037B2
(en)
|
2017-03-23 |
2022-05-26 |
Hanmi Pharm. Co., Ltd. |
Insulin analog complex with reduced affinity for insulin receptor and use thereof
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
CN110505885A
(en)
|
2017-04-05 |
2019-11-26 |
诺和诺德股份有限公司 |
Insulin-Fc the conjugate that oligomer extends
|
CN110709417B
(en)
|
2017-04-07 |
2023-10-31 |
美天施生物科技有限责任两合公司 |
Human IgG with mutation 4 Is a polypeptide of (2)
|
TWI788340B
(en)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
Anti-icos agonist antibodies and uses thereof
|
AU2018253176B2
(en)
|
2017-04-13 |
2023-02-02 |
Agenus Inc. |
Anti-CD137 antibodies and methods of use thereof
|
JOP20190248A1
(en)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
Trem2 antigen binding proteins and uses thereof
|
AU2018255938A1
(en)
|
2017-04-21 |
2019-10-31 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
US11643473B2
(en)
|
2017-04-24 |
2023-05-09 |
Alexion Pharmaceuticals, Inc. |
Antibody immune cell inhibitor fusion proteins
|
WO2018201087A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
SI3618863T1
(en)
|
2017-05-01 |
2023-12-29 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
CN111094335B
(en)
|
2017-05-15 |
2022-08-23 |
罗切斯特大学 |
Broadly neutralizing anti-influenza monoclonal antibodies and uses thereof
|
EP3630162A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
EP3630813A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
JOP20190271A1
(en)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use for immune related disorders
|
CN116333129A
(en)
|
2017-05-25 |
2023-06-27 |
百时美施贵宝公司 |
Antibodies comprising modified heavy chain constant regions
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
EP3642237A2
(en)
|
2017-06-20 |
2020-04-29 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
AU2018288803A1
(en)
|
2017-06-20 |
2020-02-06 |
Teneoone, Inc. |
Anti-BCMA heavy chain-only antibodies
|
CN111094559A
(en)
|
2017-07-07 |
2020-05-01 |
韩美药品株式会社 |
Novel therapeutic enzyme fusion proteins and uses thereof
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
DK3658184T3
(en)
|
2017-07-27 |
2023-11-27 |
Alexion Pharma Inc |
HIGHLY CONCENTRATED ANTI-C5 ANTIBODY FORMULATIONS
|
CN111094352A
(en)
|
2017-08-25 |
2020-05-01 |
戊瑞治疗有限公司 |
B7-H4 antibodies and methods of use thereof
|
KR20200090742A
(en)
|
2017-08-28 |
2020-07-29 |
알토 바이오사이언스 엘엘씨 |
IL-15 based fusion to IL-7 and IL-21
|
SG11202002093TA
(en)
|
2017-09-13 |
2020-04-29 |
Teneobio Inc |
Heavy chain antibodies binding to ectoenzymes
|
BR112020006189A2
(en)
|
2017-09-28 |
2020-10-13 |
Hanmi Pharm. Co., Ltd. |
glucagon-like peptide-2 conjugate (glp-2), derived from glp-2 comprising an amino acid sequence and its preparation method, isolated nucleic acid encoding the glp-2 derivative, recombinant expression vector comprising the acid nucleic, transformant comprising the recombinant expression vector, pharmaceutical composition to prevent or treat one or more selected diseases
|
KR20190036956A
(en)
|
2017-09-28 |
2019-04-05 |
한미약품 주식회사 |
A long acting single chain insulin analog and a conjugate thereof
|
JP7377195B2
(en)
|
2017-09-29 |
2023-11-09 |
ハンミ ファーマシューティカル カンパニー リミテッド |
Protein conjugate containing a non-peptidic polymer-bonded fatty acid derivative compound as a linker and method for producing the same
|
WO2019066603A1
(en)
|
2017-09-29 |
2019-04-04 |
한미약품 주식회사 |
Persistent protein conjugate with improved efficiency
|
CN111655268B
(en)
|
2017-10-04 |
2024-03-26 |
艾维迪提生物科学公司 |
Nucleic acid-polypeptide compositions and uses thereof
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
Human antibodies to thomsen-nouvelle (tn) antigen
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
US10538583B2
(en)
|
2017-10-31 |
2020-01-21 |
Staten Biotechnology B.V. |
Anti-APOC3 antibodies and compositions thereof
|
PE20210119A1
(en)
|
2017-10-31 |
2021-01-19 |
Staten Biotechnology B V |
ANTI-APOC3 ANTIBODIES AND METHODS OF USE OF THEM
|
KR20240007965A
(en)
|
2017-12-06 |
2024-01-17 |
어비디티 바이오사이언시스 인크. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
CN111601613A
(en)
|
2017-12-22 |
2020-08-28 |
诺华股份有限公司 |
Methods of treating metabolic disorders with FGF21 variants
|
EA202091239A1
(en)
|
2017-12-22 |
2020-09-09 |
Ханми Фарм. Ко., Лтд. |
FUSION PROTEIN BASED ON A THERAPEUTIC ENZYME WITH A NEW STRUCTURE AND ITS APPLICATION
|
KR20200104342A
(en)
|
2017-12-22 |
2020-09-03 |
테네오바이오, 인코포레이티드 |
Heavy chain antibody that binds to CD22
|
JP7284759B2
(en)
|
2017-12-27 |
2023-05-31 |
ブリストル-マイヤーズ スクイブ カンパニー |
ANTI-CD40 ANTIBODY AND USES THEREOF
|
JP2021508479A
(en)
*
|
2017-12-27 |
2021-03-11 |
テネオバイオ, インコーポレイテッド |
CD3 delta and CD3 epsilon on heterodimer-specific antibodies
|
WO2019129054A1
(en)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
Triabody, preparation method and use thereof
|
JP7339262B2
(en)
|
2018-01-12 |
2023-09-05 |
アムジェン インコーポレイテッド |
PAC1 antibody and uses thereof
|
KR20200108870A
(en)
|
2018-01-12 |
2020-09-21 |
브리스톨-마이어스 스큅 컴퍼니 |
Antibodies to TIM3 and uses thereof
|
EP3755707A1
(en)
|
2018-02-20 |
2020-12-30 |
Seagen Inc. |
Hydrophobic auristatin f compounds and conjugates thereof
|
CA3091144A1
(en)
*
|
2018-03-01 |
2019-09-06 |
Igm Biosciences, Inc. |
Igm fc and j-chain mutations that affect igm serum half-life
|
WO2019169212A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
MX2020009861A
(en)
|
2018-03-23 |
2020-10-08 |
Bristol Myers Squibb Co |
Antibodies against mica and/or micb and uses thereof.
|
TW202003011A
(en)
|
2018-03-26 |
2020-01-16 |
美商艾爾特生物科技責任有限公司 |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
CN110305210B
(en)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
Novel antibody molecules, methods of making and uses thereof
|
WO2019184909A1
(en)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
Novel antibody molecule, and preparation method and use thereof
|
US20210046189A1
(en)
|
2018-03-30 |
2021-02-18 |
HANMl PHARM. CO., LTD. |
Long-acting protein conjugates for brain targeting, a preparation method thereof, and a composition comprising the same
|
MA52190A
(en)
|
2018-04-02 |
2021-02-17 |
Bristol Myers Squibb Co |
ANTI-TREM-1 ANTIBODIES AND ASSOCIATED USES
|
US11820801B2
(en)
|
2018-04-26 |
2023-11-21 |
Good T Cells, Inc. |
Fusion protein, and pharmaceutical composition for preventing or treating cancer, containing same
|
CA3096703A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
AU2019265699A1
(en)
|
2018-05-08 |
2021-01-07 |
Amgen Inc. |
Bispecific antibodies with cleavable C-terminal charge-paired tags
|
AR126019A1
(en)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
|
JP7398396B2
(en)
|
2018-06-01 |
2023-12-14 |
ノバルティス アーゲー |
Binding molecules for BCMA and their uses
|
TW202015740A
(en)
|
2018-06-07 |
2020-05-01 |
美商西雅圖遺傳學公司 |
Camptothecin conjugates
|
TW202016151A
(en)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
Multi-specific binding proteins for cancer treatment
|
BR112020025111A2
(en)
|
2018-06-15 |
2021-04-06 |
Proclara Biosciences, Inc. |
REASON FOR GENERAL AMYLOID INTERACTION (GAIM)
|
KR20210032311A
(en)
|
2018-07-20 |
2021-03-24 |
테네오바이오, 인코포레이티드 |
Heavy chain antibody that binds to CD19
|
MX2021000786A
(en)
|
2018-07-20 |
2021-06-15 |
Pf Medicament |
Receptor for vista.
|
US20210347849A1
(en)
|
2018-07-24 |
2021-11-11 |
Good T Cells, Inc. |
Composition for Preventing or Treating Immune-Related Diseases
|
CA3113057A1
(en)
|
2018-09-21 |
2020-03-26 |
Teneobio, Inc. |
Methods for purifying heterodimeric, multispecific antibodies
|
CN110964116A
(en)
|
2018-09-26 |
2020-04-07 |
北京辅仁瑞辉生物医药研究院有限公司 |
GLP1-Fc fusion proteins and conjugates thereof
|
CA3113575A1
(en)
|
2018-10-03 |
2020-04-09 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
US20210338779A1
(en)
|
2018-10-04 |
2021-11-04 |
Hanmi Pharm. Co., Ltd |
Therapeutic use of glucagon and combination including the same
|
CN112839681A
(en)
|
2018-10-10 |
2021-05-25 |
诺和诺德股份有限公司 |
Oligomer-extended insulin-Fc conjugates and medical uses thereof
|
EP3863722A2
(en)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
UY38407A
(en)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
TREM2 STABILIZING ANTIBODIES
|
TWI824043B
(en)
|
2018-10-25 |
2023-12-01 |
西班牙商瑪製藥股份有限公司 |
Drug antibody conjugates
|
US20210388106A1
(en)
|
2018-10-26 |
2021-12-16 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd38
|
WO2020102501A1
(en)
|
2018-11-16 |
2020-05-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a antibodies and uses thereof
|
CN113348177A
(en)
|
2018-11-28 |
2021-09-03 |
百时美施贵宝公司 |
Antibodies comprising modified heavy chain constant regions
|
KR102630499B1
(en)
|
2018-12-21 |
2024-01-30 |
어비디티 바이오사이언시스 인크. |
Antitransferrin receptor antibodies and uses thereof
|
EP3900735A4
(en)
|
2018-12-21 |
2022-09-07 |
Hanmi Pharm. Co., Ltd. |
Pharmaceutical composition comprising insulin and triple agonist having activity with respect to all of glucagon and glp-1 and gip receptor
|
KR20200078414A
(en)
|
2018-12-21 |
2020-07-01 |
한미약품 주식회사 |
A pharmaceutical composition comprising insulin and glucagon
|
PE20212305A1
(en)
|
2019-01-22 |
2021-12-10 |
Bristol Myers Squibb Co |
ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES OF THESE
|
MA55080A
(en)
|
2019-02-26 |
2022-01-05 |
Inspirna Inc |
HIGH AFFINITY ANTI-MERTK ANTIBODIES AND ASSOCIATED USES
|
AU2020252556A1
(en)
|
2019-04-05 |
2021-10-21 |
Teneobio, Inc. |
Heavy chain antibodies binding to PSMA
|
KR102524577B1
(en)
|
2019-04-22 |
2023-04-21 |
전남대학교산학협력단 |
Flagellin fusion protein and uses thereof
|
US20220409734A1
(en)
|
2019-05-10 |
2022-12-29 |
Yutaka Nishimoto |
Antibody drug conjugates
|
AU2020279974A1
(en)
|
2019-05-21 |
2021-11-18 |
Novartis Ag |
CD19 binding molecules and uses thereof
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
MA56033A
(en)
|
2019-05-24 |
2022-04-06 |
Sanofi Sa |
METHODS OF TREATMENT FOR GENERALIZED SCLERODERMA
|
WO2020243477A2
(en)
|
2019-05-30 |
2020-12-03 |
Amgen Inc. |
Engineering the hinge region to drive antibody dimerization
|
CN114375297A
(en)
|
2019-06-06 |
2022-04-19 |
艾维迪提生物科学公司 |
UNA imides and uses thereof
|
JP2022535588A
(en)
|
2019-06-06 |
2022-08-09 |
アビディティー バイオサイエンシーズ,インク. |
NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
WO2020245420A1
(en)
|
2019-06-07 |
2020-12-10 |
Argenx Bvba |
PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
|
CA3140816A1
(en)
|
2019-06-14 |
2020-12-17 |
Nathan Trinklein |
Multispecific heavy chain antibodies binding to cd22 and cd3
|
CA3143524A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
PL3936142T3
(en)
|
2019-06-28 |
2024-05-06 |
Hanmi Pharm. Co., Ltd. |
Triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors for treating liver disease
|
CN114174536A
(en)
|
2019-07-15 |
2022-03-11 |
百时美施贵宝公司 |
anti-TREM-1 antibodies and uses thereof
|
CN114144435B
(en)
|
2019-07-15 |
2024-06-25 |
百时美施贵宝公司 |
Antibodies against human TREM-1 and uses thereof
|
US11717577B2
(en)
|
2019-07-18 |
2023-08-08 |
Hanmi Pharm. Co., Ltd. |
Method for preparing long-acting drug conjugate through preparation of intermediate
|
EP4004050A2
(en)
|
2019-07-30 |
2022-06-01 |
QLSF Biotherapeutics Inc. |
Multispecific binding compound that bind to lfrrc15 and cd3
|
MX2022001882A
(en)
|
2019-08-12 |
2022-05-30 |
Aptevo Res & Development Llc |
4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40.
|
TW202122420A
(en)
|
2019-08-30 |
2021-06-16 |
美商艾吉納斯公司 |
Anti-cd96 antibodies and methods of use thereof
|
EP4025253B1
(en)
|
2019-09-05 |
2024-03-20 |
Pharma Mar, S.A. |
Drug antibody conjugates
|
TW202124446A
(en)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
Combination therapies with entpd2 antibodies
|
JP2022548881A
(en)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
|
US20210138077A1
(en)
|
2019-09-19 |
2021-05-13 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
JP2022550851A
(en)
|
2019-10-04 |
2022-12-05 |
シージェン インコーポレイテッド |
camptothecin peptide conjugate
|
JP2022551282A
(en)
|
2019-10-04 |
2022-12-08 |
ハンミ ファーマシューティカル カンパニー リミテッド |
Compositions Comprising Glucagon and GLP-1 Receptor and GIP Receptor Dual Agonists and Therapeutic Uses Thereof
|
US20220380487A1
(en)
|
2019-10-24 |
2022-12-01 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
CA3160482A1
(en)
|
2019-11-08 |
2021-05-14 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-igg molecules
|
AU2020386005A1
(en)
|
2019-11-19 |
2022-05-26 |
Amgen Inc. |
Novel multispecific antibody format
|
KR20220114559A
(en)
|
2019-12-18 |
2022-08-17 |
테네오포, 인코포레이티드 |
heavy chain antibody that binds to CD38
|
CA3164129A1
(en)
|
2019-12-20 |
2021-06-24 |
Amgen Inc. |
Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
KR20210082120A
(en)
|
2019-12-24 |
2021-07-02 |
한미약품 주식회사 |
A pharmaceutical composition for preventing or treating metabolic bone disorders, comprising GLP-2 or a conjugate thereof
|
EP4104849A4
(en)
|
2020-01-13 |
2024-03-27 |
Hanmi Pharm. Co., Ltd. |
Therapeutic use of long-acting conjugate of triple agonist having activity with respect to all of glucagon and glp-1 and gip receptors against lung disease
|
AU2021226341A1
(en)
|
2020-02-25 |
2022-09-29 |
Mediboston Limited |
Camptothecin derivatives and conjugates thereof
|
EP4121063A4
(en)
|
2020-03-19 |
2024-07-03 |
Avidity Biosciences Inc |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
WO2021195574A1
(en)
*
|
2020-03-27 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
KR20220161378A
(en)
|
2020-03-27 |
2022-12-06 |
어비디티 바이오사이언시스 인크. |
Compositions and methods for the treatment of muscular dystrophy
|
KR20210121585A
(en)
|
2020-03-30 |
2021-10-08 |
한국세라믹기술원 |
Z domain-calsequestrin fusion protein with improved reactivity, stability and antibody recovery and method of isolating and purifying antibody using the same
|
JP2023519930A
(en)
|
2020-04-01 |
2023-05-15 |
ユニバーシティ オブ ロチェスター |
Monoclonal Antibodies Against Hemagglutinin (HA) and Neuraminidase (NA) of Influenza H3N2 Virus
|
US20230159607A1
(en)
|
2020-04-03 |
2023-05-25 |
Hanmi Pharm. Co., Ltd. |
Pharmaceutical composition for preventing or treating mucositis induced by radiotherapy, chemotherapy, or combination thereof, comprising glp-2 derivatives or long-acting conjugate of same
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
JP2023522102A
(en)
|
2020-04-20 |
2023-05-26 |
ジェンザイム・コーポレーション |
Humanized anti-complement factor Bb antibody and uses thereof
|
JP2023521491A
(en)
|
2020-04-20 |
2023-05-24 |
ハンミ ファーマシューティカル カンパニー リミテッド |
A pharmaceutical composition for prevention or treatment of hyperlipidemia and a method for prevention or treatment containing a triple activator or a conjugate thereof having activity against all of glucagon, GLP-1 and GIP receptor
|
WO2021214126A1
(en)
|
2020-04-21 |
2021-10-28 |
Pharma Mar, S.A. |
Drug antibody conjugates
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
UY39191A
(en)
|
2020-04-29 |
2021-11-30 |
Teneobio Inc |
MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
|
AU2021263926A1
(en)
|
2020-04-29 |
2023-01-19 |
Teneoone, Inc. |
Methods of treating multiple myeloma
|
CN115894703A
(en)
|
2020-04-29 |
2023-04-04 |
特尼奥生物股份有限公司 |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
JP2023528235A
(en)
|
2020-05-17 |
2023-07-04 |
アストラゼネカ・ユーケイ・リミテッド |
SARS-CoV-2 Antibodies and Methods of Selecting and Using The Same
|
WO2021235913A1
(en)
|
2020-05-22 |
2021-11-25 |
한미약품 주식회사 |
Liquid formulation of long-acting conjugate of glp-2
|
BR112022023738A2
(en)
|
2020-05-22 |
2023-01-31 |
Hanmi Pharm Ind Co Ltd |
LIQUID FORMULATION
|
JP2023526551A
(en)
|
2020-05-22 |
2023-06-21 |
ハンミ ファーマシューティカル カンパニー リミテッド |
Liquid formulation of long-acting conjugates of glucagon derivatives
|
WO2021235916A1
(en)
|
2020-05-22 |
2021-11-25 |
한미약품 주식회사 |
Liquid preparation of long-acting conjugate of glucagon/glp-1/gip trigonal agonist
|
CN116209459A
(en)
|
2020-06-26 |
2023-06-02 |
美国安进公司 |
IL-10 muteins and fusion proteins thereof
|
CN116472049A
(en)
|
2020-06-30 |
2023-07-21 |
特尼奥生物股份有限公司 |
Multispecific antibodies that bind to BCMA
|
KR20220009354A
(en)
|
2020-07-15 |
2022-01-24 |
한미약품 주식회사 |
Therapeutic use of a glucagon derivative or a conjugate thereof for liver disease
|
CA3186416A1
(en)
|
2020-07-17 |
2022-01-20 |
John A. Barrett |
Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
|
WO2022015115A1
(en)
|
2020-07-17 |
2022-01-20 |
한미약품 주식회사 |
Therapeutic use of combination containing triple agonistic long-acting conjugate or triple agonist
|
WO2022017309A1
(en)
|
2020-07-24 |
2022-01-27 |
江苏晟斯生物制药有限公司 |
Insulin-fc fusion protein and application thereof
|
WO2022031978A1
(en)
|
2020-08-06 |
2022-02-10 |
Bioverativ Usa Inc. |
Inflammatory cytokines and fatigue in subject with a complement mediated disease
|
BR112023002234A2
(en)
|
2020-08-10 |
2023-03-07 |
Astrazeneca Uk Ltd |
SARS-COV-2 ANTIBODIES FOR TREATMENT AND PREVENTION OF COVID-19
|
TW202220700A
(en)
|
2020-08-14 |
2022-06-01 |
南韓商韓美藥品股份有限公司 |
Pharmaceutical composition comprising long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
|
US20240024426A1
(en)
|
2020-08-14 |
2024-01-25 |
Hanmi Pharm. Co., Ltd. |
Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors
|
JP2023538897A
(en)
|
2020-08-20 |
2023-09-12 |
アムジエン・インコーポレーテツド |
Antigen binding proteins with non-canonical disulfides in the Fab region
|
WO2022065899A1
(en)
|
2020-09-25 |
2022-03-31 |
한미약품 주식회사 |
Therapeutic use of long-acting conjugate of triple agonist acting on all of glucagon, glp-1 and gip receptors against multiple sclerosis
|
CN116437967A
(en)
|
2020-09-25 |
2023-07-14 |
韩美药品株式会社 |
Pharmaceutical composition for preventing or treating bone diseases comprising triple agonists or conjugates thereof having activity on all of glucagon, GLP-1 and GLP receptors
|
JP2023543036A
(en)
|
2020-09-25 |
2023-10-12 |
ハンミ ファーマシューティカル カンパニー リミテッド |
Use of a triple activator or a conjugate thereof having activity against all of glucagon, GLP-1 and GIP receptors for the treatment of neurodegenerative diseases
|
JP2023544769A
(en)
|
2020-10-07 |
2023-10-25 |
アムジエン・インコーポレーテツド |
Rational selection of building blocks for the construction of multispecific antibodies
|
WO2022080986A1
(en)
|
2020-10-16 |
2022-04-21 |
한미약품 주식회사 |
Glp-1/gip dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising same
|
KR20220050824A
(en)
|
2020-10-16 |
2022-04-25 |
한미약품 주식회사 |
Trigonal glucagon/GLP-1/GIP receptor agonist for use in the treatment of sequelae of respiratory infection
|
KR20220050821A
(en)
|
2020-10-16 |
2022-04-25 |
한미약품 주식회사 |
Pharmaceutical composition for preventing or treating vasculitis comprising glucagon/GLP-1/GIP triple agonist or long acting conjugate thereof
|
US20240084014A1
(en)
|
2020-10-16 |
2024-03-14 |
Qlsf Biotherapeutics, Inc. |
Multispecific binding compounds that bind to pd-l1
|
JP2023546089A
(en)
|
2020-10-16 |
2023-11-01 |
ハンミ ファーマシューティカルズ カンパニー リミテッド |
Pharmaceutical composition for the prevention or treatment of lupus-related diseases containing a GIP derivative or a long-acting conjugate thereof
|
US20230381331A1
(en)
|
2020-10-16 |
2023-11-30 |
Hanmi Pharm. Co., Ltd. |
Gip derivative, long-acting conjugate thereof, and pharmaceutical composition comprising same
|
WO2022080989A1
(en)
|
2020-10-16 |
2022-04-21 |
한미약품 주식회사 |
Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases
|
JP2023548878A
(en)
|
2020-11-04 |
2023-11-21 |
ザ ロックフェラー ユニバーシティー |
Neutralizing anti-SARS-COV-2 antibody
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
US20220168330A1
(en)
|
2020-11-09 |
2022-06-02 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
TW202233663A
(en)
|
2020-11-10 |
2022-09-01 |
美商安進公司 |
Novel linkers of multispecific antigen binding domains
|
CN116419760A
(en)
|
2020-11-13 |
2023-07-11 |
韩美药品株式会社 |
Use of therapeutic enzyme fusion proteins for the prevention and treatment of kidney diseases caused by or associated with fabry disease
|
EP4245310A1
(en)
|
2020-11-13 |
2023-09-20 |
Hanmi Pharm. Co., Ltd. |
Use of therapeutic enzyme fusion protein in preventing and treating neuropathy attributed to or associated with farbry's disease
|
TW202233684A
(en)
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
Heavy chain antibodies binding to folate receptor alpha
|
AU2021390501A1
(en)
|
2020-12-01 |
2023-06-29 |
Aptevo Research And Development Llc |
Heterodimeric psma and cd3-binding bispecific antibodies
|
IL303295A
(en)
|
2020-12-07 |
2023-07-01 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
WO2022131889A1
(en)
|
2020-12-16 |
2022-06-23 |
주식회사 굳티셀 |
Use of taci protein
|
US20230382974A1
(en)
|
2020-12-24 |
2023-11-30 |
Hanmi Pharm. Co., Ltd. |
Novel triple agonist having activities on all of glucagon, glp-1, and gip receptors and use thereof
|
EP4302776A1
(en)
|
2020-12-24 |
2024-01-10 |
Hanmi Pharm. Co., Ltd. |
Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
|
WO2022147463A2
(en)
|
2020-12-31 |
2022-07-07 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
US20220227844A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
JP2024505943A
(en)
|
2021-01-29 |
2024-02-08 |
ハンミ ファーマシューティカルズ カンパニー リミテッド |
Pharmaceutical composition for the prevention or treatment of lung diseases containing a GIP derivative or a long-acting conjugate thereof
|
AU2022226277A1
(en)
|
2021-02-25 |
2023-08-31 |
Teneobio, Inc. |
Anti-psma antibodies and car-t structures
|
US20240182597A1
(en)
|
2021-02-26 |
2024-06-06 |
Teneobio, Inc. |
Anti-muc1-c antibodies and car-t structures
|
IL305886A
(en)
|
2021-03-18 |
2023-11-01 |
Seagen Inc |
Selective drug release from internalized conjugates of biologically active compounds
|
MX2023010902A
(en)
|
2021-03-18 |
2023-09-27 |
Seagen Inc |
Selective drug release from internalized conjugates of biologically active compounds.
|
JP2024513837A
(en)
|
2021-03-31 |
2024-03-27 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
Reducing surgery-related hemolysis in patients with cold agglutinin disease
|
MX2023010926A
(en)
|
2021-03-31 |
2023-09-27 |
Hanmi Pharmaceutical Co Ltd |
Novel immunoactive interleukin 2 analog conjugate and method for preparing same.
|
TW202304994A
(en)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
Agonistic anti-il-2r antibodies and methods of use
|
JP2024514530A
(en)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Antibodies against truncated CDCP1 and uses thereof
|
JP2024514107A
(en)
|
2021-04-06 |
2024-03-28 |
テネオバイオ, インコーポレイテッド |
Anti-CD19 antibody and CAR-T construct
|
US20240197834A1
(en)
|
2021-04-09 |
2024-06-20 |
Hanmi Pharm. Co., Ltd. |
Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative
|
PE20240656A1
(en)
|
2021-04-16 |
2024-04-04 |
Teneobio Inc |
ANTI-CD20 ANTIBODIES AND CAR-T STRUCTURES
|
JP2024515301A
(en)
|
2021-04-20 |
2024-04-08 |
アムジエン・インコーポレーテツド |
Balanced charge distribution in electrostatic steering of chain pairing in the association of multispecific and monovalent IGG molecules
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
WO2022271987A1
(en)
|
2021-06-23 |
2022-12-29 |
TeneoFour, Inc. |
Anti-cd38 antibodies and epitopes of same
|
WO2022272018A1
(en)
|
2021-06-25 |
2022-12-29 |
Amgen Inc. |
Treatment of cardiovascular disease with trem-1 antigen binding proteins
|
KR20230004135A
(en)
|
2021-06-30 |
2023-01-06 |
한미약품 주식회사 |
Therapeutic use of a combination comprising a trigonal glucagon/GLP-1/GIP receptor agonist
|
WO2023004197A1
(en)
|
2021-07-23 |
2023-01-26 |
Teneoten, Inc. |
Heavy chain antibodies binding to hepatitis b surface antigen
|
AR126970A1
(en)
|
2021-09-02 |
2023-12-06 |
Djs Antibodies Ltd |
POLYPETIDES
|
WO2023043953A1
(en)
|
2021-09-16 |
2023-03-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
CA3232806A1
(en)
|
2021-09-30 |
2023-04-06 |
Seagen Inc. |
B7-h4 antibody-drug conjugates for the treatment of cancer
|
US20230192843A1
(en)
|
2021-10-14 |
2023-06-22 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
TW202342095A
(en)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
Composition for treatment and prevention of covid-19
|
WO2023091968A1
(en)
|
2021-11-17 |
2023-05-25 |
Disc Medicine, Inc. |
Methods for treating anemia of kidney disease
|
TW202337904A
(en)
|
2022-01-07 |
2023-10-01 |
美商壯生和壯生企業創新公司 |
Materials and methods of il-1β binding proteins
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023173084A1
(en)
|
2022-03-11 |
2023-09-14 |
University Of Rochester |
Cyclopeptibodies and uses thereof
|
US20230381321A1
(en)
|
2022-03-17 |
2023-11-30 |
Seagan Inc., |
Camptothecin conjugates
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
US20240117021A1
(en)
|
2022-06-15 |
2024-04-11 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
WO2023242371A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
Ph-dependent hsa-binding molecules and methods of use
|
WO2023250507A1
(en)
|
2022-06-24 |
2023-12-28 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|
WO2024003376A1
(en)
|
2022-07-01 |
2024-01-04 |
Alk-Abelló A/S |
Displacers of ige-fceri
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
US20240108744A1
(en)
|
2022-07-27 |
2024-04-04 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
WO2024026494A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Viral particles retargeted to transferrin receptor 1
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024026470A2
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:payload fusions and methods of use thereof
|
US11773160B1
(en)
|
2022-08-05 |
2023-10-03 |
Anaveon AG |
Immune-stimulating IL-2 fusion proteins
|
WO2024036139A2
(en)
|
2022-08-09 |
2024-02-15 |
Qlsf Biotherapeutics, Inc. |
Antibodies binding to clec12a
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
US20240173426A1
(en)
|
2022-11-14 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
US20240158515A1
(en)
|
2022-11-14 |
2024-05-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|